[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGStp6Txv4DjrkoAM-qd92CDmtgIERdyqGFFQo0uo_DI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":61,"rows":68},"University of Copenhagen",[4],453,false,45,5,4361749,6,396,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Obesity",69,{"name":18,"count":19},"Healthy",42,{"name":21,"count":22},"Metabolic Syndrome",19,{"name":24,"count":25},"Cardiovascular Disease",13,{"name":27,"count":28},"Overweight",12,{"name":30,"count":28},"Insulin Resistance",{"name":32,"count":33},"Type 2 Diabetes",10,{"name":35,"count":33},"Insulin Sensitivity",[37,42,47,52,56],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05010356","Insulin Sensitivity After Breast Cancer","2022-12","Insulin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06654986","Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.","2026-12-18","Salmeterol + amino acid availability",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06657547","Urinary Concentration After Salmeterol","2026-12-31","Salmeterol inhalation and urine samples",{"nctId":53,"briefTitle":54,"date":50,"intervention":55},"NCT06655012","Salmeterol Effect on Exercise Performance","Salmeterol",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05233722","mTOR as Mediator of Insulin Sensitivity Study","2029-06","Rapamycin",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,109,139,157,176,194,213,238,264,282,300,328,346,364,390,408,435,459,495,528,559,577,602,628,646,672,698,729,752,778,830,865,902,935,971,996,1014,1041,1059,1077,1095,1113,1139,1164,1187,1205,1228,1266,1284,1306,1324,1347,1374,1397,1422,1440,1465,1489,1511,1529,1547,1573,1598,1621,1646],{"intervention":41,"totalTrials":70,"cells":71},2,{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[],{"trials":78,"activeCount":74},[],{"trials":80,"activeCount":74},[],{"trials":82,"activeCount":74},[],{"trials":84,"activeCount":108,"soonestReadout":40},[85,97],{"nctId":38,"briefTitle":39,"status":86,"phases":87,"primaryCompletion":40,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":96},"RECRUITING",[67],"2026-09","2021-08",24,[92,93,94,95],"Insulin Sensitivity\u002FResistance","Breast Cancer","Survivorship","Metabolic Disturbance",[41],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":107},"NCT03203317","Myocellular Signalling in Skeletal Muscle","COMPLETED",[67],"2017-07-26","2017-05-01",8,[106,35],"Exercise",[41],1,{"intervention":55,"totalTrials":70,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":131},{"trials":112,"activeCount":74},[],{"trials":114,"activeCount":74},[],{"trials":116,"activeCount":74},[],{"trials":118,"activeCount":74},[],{"trials":120,"activeCount":74},[121],{"nctId":122,"briefTitle":123,"status":100,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT02558088","Pharmacological Properties of Salmeterol",[66],"2016-07","2014-09",11,[129],"Pharmacokinetics in Healthy Young Men",[55],{"trials":132,"activeCount":108,"soonestReadout":50},[133],{"nctId":53,"briefTitle":54,"status":86,"phases":134,"primaryCompletion":50,"completion":50,"start":135,"enrollment":136,"conditions":137,"interventions":138},[67],"2024-10-31",36,[18],[55],{"intervention":51,"totalTrials":108,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":142,"activeCount":74},[],{"trials":144,"activeCount":74},[],{"trials":146,"activeCount":74},[],{"trials":148,"activeCount":74},[],{"trials":150,"activeCount":74},[],{"trials":152,"activeCount":108,"soonestReadout":50},[153],{"nctId":48,"briefTitle":49,"status":86,"phases":154,"primaryCompletion":50,"completion":50,"start":135,"enrollment":90,"conditions":155,"interventions":156},[67],[18],[51],{"intervention":46,"totalTrials":108,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":160,"activeCount":74},[],{"trials":162,"activeCount":74},[],{"trials":164,"activeCount":74},[],{"trials":166,"activeCount":74},[],{"trials":168,"activeCount":74},[],{"trials":170,"activeCount":108,"soonestReadout":45},[171],{"nctId":43,"briefTitle":44,"status":86,"phases":172,"primaryCompletion":45,"completion":45,"start":135,"enrollment":136,"conditions":173,"interventions":174},[67],[18],[46,175],"Salmeterol + placebo",{"intervention":175,"totalTrials":108,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":179,"activeCount":74},[],{"trials":181,"activeCount":74},[],{"trials":183,"activeCount":74},[],{"trials":185,"activeCount":74},[],{"trials":187,"activeCount":74},[],{"trials":189,"activeCount":108,"soonestReadout":45},[190],{"nctId":43,"briefTitle":44,"status":86,"phases":191,"primaryCompletion":45,"completion":45,"start":135,"enrollment":136,"conditions":192,"interventions":193},[67],[18],[46,175],{"intervention":60,"totalTrials":108,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":206},{"trials":197,"activeCount":74},[],{"trials":199,"activeCount":74},[],{"trials":201,"activeCount":74},[],{"trials":203,"activeCount":74},[],{"trials":205,"activeCount":74},[],{"trials":207,"activeCount":108,"soonestReadout":59},[208],{"nctId":57,"briefTitle":58,"status":86,"phases":209,"primaryCompletion":59,"completion":59,"start":210,"enrollment":33,"conditions":211,"interventions":212},[67],"2022-02-10",[35],[60],{"intervention":214,"totalTrials":108,"cells":215},"Simvastatin",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":236},{"trials":217,"activeCount":74},[],{"trials":219,"activeCount":74},[],{"trials":221,"activeCount":74},[],{"trials":223,"activeCount":74},[],{"trials":225,"activeCount":74},[226],{"nctId":227,"briefTitle":228,"status":100,"phases":229,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT02255682","Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being",[66],"2016-12","2015-01",35,[24,234],"Diabetes Mellitus",[214],{"trials":237,"activeCount":74},[],{"intervention":239,"totalTrials":108,"cells":240},"Entresto",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":262},{"trials":242,"activeCount":74},[],{"trials":244,"activeCount":74},[],{"trials":246,"activeCount":74},[],{"trials":248,"activeCount":74},[],{"trials":250,"activeCount":74},[251],{"nctId":252,"briefTitle":253,"status":100,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":28,"conditions":257,"interventions":259},"NCT03893526","Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes",[66],"2021-03-01","2019-01-25",[258],"Type2 Diabetes",[239,260,261],"Sitagliptin","Valsartan",{"trials":263,"activeCount":74},[],{"intervention":260,"totalTrials":108,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":74},[],{"trials":269,"activeCount":74},[],{"trials":271,"activeCount":74},[],{"trials":273,"activeCount":74},[],{"trials":275,"activeCount":74},[276],{"nctId":252,"briefTitle":253,"status":100,"phases":277,"primaryCompletion":255,"completion":255,"start":256,"enrollment":28,"conditions":278,"interventions":279},[66],[258],[239,260,261],{"trials":281,"activeCount":74},[],{"intervention":261,"totalTrials":108,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":298},{"trials":285,"activeCount":74},[],{"trials":287,"activeCount":74},[],{"trials":289,"activeCount":74},[],{"trials":291,"activeCount":74},[],{"trials":293,"activeCount":74},[294],{"nctId":252,"briefTitle":253,"status":100,"phases":295,"primaryCompletion":255,"completion":255,"start":256,"enrollment":28,"conditions":296,"interventions":297},[66],[258],[239,260,261],{"trials":299,"activeCount":74},[],{"intervention":301,"totalTrials":108,"cells":302},"Training+Simvastatin+Q10-placebo",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":326},{"trials":304,"activeCount":74},[],{"trials":306,"activeCount":74},[],{"trials":308,"activeCount":74},[],{"trials":310,"activeCount":74},[],{"trials":312,"activeCount":74},[313],{"nctId":314,"briefTitle":315,"status":316,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},"NCT02796378","Living With Statins - Interventional Exercise Study","UNKNOWN",[66],"2021-07","2021-12","2016-06",30,[24,234],[301,324,325],"Training+Simvastatin-placebo+Q10-placebo","Training+Simvastatin+Q10",{"trials":327,"activeCount":74},[],{"intervention":324,"totalTrials":108,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":344},{"trials":331,"activeCount":74},[],{"trials":333,"activeCount":74},[],{"trials":335,"activeCount":74},[],{"trials":337,"activeCount":74},[],{"trials":339,"activeCount":74},[340],{"nctId":314,"briefTitle":315,"status":316,"phases":341,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":342,"interventions":343},[66],[24,234],[301,324,325],{"trials":345,"activeCount":74},[],{"intervention":325,"totalTrials":108,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":362},{"trials":349,"activeCount":74},[],{"trials":351,"activeCount":74},[],{"trials":353,"activeCount":74},[],{"trials":355,"activeCount":74},[],{"trials":357,"activeCount":74},[358],{"nctId":314,"briefTitle":315,"status":316,"phases":359,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":360,"interventions":361},[66],[24,234],[301,324,325],{"trials":363,"activeCount":74},[],{"intervention":365,"totalTrials":108,"cells":366},"Topiramate 96 mg daily",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":388},{"trials":368,"activeCount":74},[],{"trials":370,"activeCount":74},[],{"trials":372,"activeCount":74},[],{"trials":374,"activeCount":74},[],{"trials":376,"activeCount":74},[377],{"nctId":378,"briefTitle":379,"status":380,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":386},"NCT02040311","Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects","TERMINATED",[66],"2002-06","2000-08",701,[15],[365,387],"Topiramate 192 mg daily",{"trials":389,"activeCount":74},[],{"intervention":387,"totalTrials":108,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":406},{"trials":393,"activeCount":74},[],{"trials":395,"activeCount":74},[],{"trials":397,"activeCount":74},[],{"trials":399,"activeCount":74},[],{"trials":401,"activeCount":74},[402],{"nctId":378,"briefTitle":379,"status":380,"phases":403,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":404,"interventions":405},[66],[15],[365,387],{"trials":407,"activeCount":74},[],{"intervention":409,"totalTrials":108,"cells":410},"Artemether-lumefantrine",{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":433},{"trials":412,"activeCount":74},[],{"trials":414,"activeCount":74},[],{"trials":416,"activeCount":74},[],{"trials":418,"activeCount":74},[],{"trials":420,"activeCount":74},[421],{"nctId":422,"briefTitle":423,"status":100,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":432},"NCT00885287","Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania",[66],"2012-10","2013-01","2009-07",830,[430,431],"Malaria, Falciparum","HIV Infections",[409],{"trials":434,"activeCount":74},[],{"intervention":436,"totalTrials":108,"cells":437},"Oxygen",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":457},{"trials":439,"activeCount":74},[],{"trials":441,"activeCount":74},[],{"trials":443,"activeCount":74},[],{"trials":445,"activeCount":74},[],{"trials":447,"activeCount":74},[448],{"nctId":449,"briefTitle":450,"status":100,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":232,"conditions":454,"interventions":456},"NCT00637936","Respiratory Effects of Perioperative Oxygen During General Anaesthesia",[66],"2008-08","2008-03",[455],"Laparotomy",[436],{"trials":458,"activeCount":74},[],{"intervention":460,"totalTrials":70,"cells":461},"Bupivacaine",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":491,"NA":493},{"trials":463,"activeCount":74},[],{"trials":465,"activeCount":74},[],{"trials":467,"activeCount":74},[],{"trials":469,"activeCount":74},[470,480],{"nctId":471,"briefTitle":472,"status":100,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT02065804","Trigger-point Blockade in Persistent Pain After Laparoscopical Groin Hernia Repair",[65],"2014-07","2013-10",14,[478],"Chronic Pain",[460],{"nctId":481,"briefTitle":482,"status":100,"phases":483,"primaryCompletion":484,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT02065219","Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair",[65],"2014-04","2015-05","2013-11",20,[489,478],"Inguinal Hernia",[460],{"trials":492,"activeCount":74},[],{"trials":494,"activeCount":74},[],{"intervention":496,"totalTrials":70,"cells":497},"Metobes-compound",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":524,"NA":526},{"trials":499,"activeCount":74},[],{"trials":501,"activeCount":74},[],{"trials":503,"activeCount":74},[],{"trials":505,"activeCount":74},[506,515],{"nctId":507,"briefTitle":508,"status":100,"phases":509,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":514},"NCT00302276","Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)",[64,65],"2004-07","2004-01",80,[15],[496],{"nctId":516,"briefTitle":517,"status":100,"phases":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":523},"NCT00302263","B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)",[64,65],"2005-04","2005-01",22,[15],[496],{"trials":525,"activeCount":74},[],{"trials":527,"activeCount":74},[],{"intervention":529,"totalTrials":108,"cells":530},"MabThera",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":532,"activeCount":74},[],{"trials":534,"activeCount":74},[],{"trials":536,"activeCount":74},[537],{"nctId":538,"briefTitle":539,"status":100,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":551},"NCT00426543","Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome",[64],"2010-06","2010-08","2007-01",21,[546,547,548,549,550],"Primary Sjögren's Syndrome","Xerostomia","Hyposalivation","Keratoconjunctivitis Sicca","Fatigue",[529,552],"Rituximab, Mabthera",{"trials":554,"activeCount":74},[],{"trials":556,"activeCount":74},[],{"trials":558,"activeCount":74},[],{"intervention":552,"totalTrials":108,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":562,"activeCount":74},[],{"trials":564,"activeCount":74},[],{"trials":566,"activeCount":74},[567],{"nctId":538,"briefTitle":539,"status":100,"phases":568,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":569,"interventions":570},[64],[546,547,548,549,550],[529,552],{"trials":572,"activeCount":74},[],{"trials":574,"activeCount":74},[],{"trials":576,"activeCount":74},[],{"intervention":578,"totalTrials":108,"cells":579},"Liraglutide",{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":581,"activeCount":74},[],{"trials":583,"activeCount":74},[],{"trials":585,"activeCount":74},[586],{"nctId":587,"briefTitle":588,"status":100,"phases":589,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":595},"NCT02082496","GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations",[64],"2016-04","2019-04","2014-06",50,[15],[578],{"trials":597,"activeCount":74},[],{"trials":599,"activeCount":74},[],{"trials":601,"activeCount":74},[],{"intervention":603,"totalTrials":108,"cells":604},"Vedolizumab",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":606,"activeCount":74},[],{"trials":608,"activeCount":74},[],{"trials":610,"activeCount":74},[611],{"nctId":612,"briefTitle":613,"status":316,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT04797325","Vedolizumab for Immune Mediated Colitis",[64],"2025-04","2021-08-30",82,[619],"Immune-Mediated Colitis",[603,621],"Prednisolone",{"trials":623,"activeCount":74},[],{"trials":625,"activeCount":74},[],{"trials":627,"activeCount":74},[],{"intervention":621,"totalTrials":108,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":631,"activeCount":74},[],{"trials":633,"activeCount":74},[],{"trials":635,"activeCount":74},[636],{"nctId":612,"briefTitle":613,"status":316,"phases":637,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":638,"interventions":639},[64],[619],[603,621],{"trials":641,"activeCount":74},[],{"trials":643,"activeCount":74},[],{"trials":645,"activeCount":74},[],{"intervention":647,"totalTrials":108,"cells":648},"Erythropoietin",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":650,"activeCount":74},[],{"trials":652,"activeCount":74},[653],{"nctId":654,"briefTitle":655,"status":100,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT01584921","Renal Effects of Erythropoietin in Humans",[63],"2013-08","2013-09","2012-03",16,[662],"Renal Effects",[647,647],{"trials":665,"activeCount":74},[],{"trials":667,"activeCount":74},[],{"trials":669,"activeCount":74},[],{"trials":671,"activeCount":74},[],{"intervention":673,"totalTrials":108,"cells":674},"L-arabinose",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":690,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":676,"activeCount":74},[],{"trials":678,"activeCount":74},[679],{"nctId":680,"briefTitle":681,"status":100,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT00302302","The Effects of L-arabinose on Intestinal Sucrase Activity in Man",[63],"2005-11","2006-01","2005-09",15,[688],"Blood Glucose",[673],{"trials":691,"activeCount":74},[],{"trials":693,"activeCount":74},[],{"trials":695,"activeCount":74},[],{"trials":697,"activeCount":74},[],{"intervention":699,"totalTrials":108,"cells":700},"Cannabidiol",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":702,"activeCount":74},[],{"trials":704,"activeCount":74},[705],{"nctId":706,"briefTitle":707,"status":100,"phases":708,"primaryCompletion":616,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":720},"NCT04585841","The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy",[63],"2022-11-01","2020-12-01",32,[713,714,715,716,717,718,719],"Lean Body Mass","Cannabis","Cancer","Nausea","Cachexia","Emesis","Appetitive Behavior",[699],{"trials":722,"activeCount":74},[],{"trials":724,"activeCount":74},[],{"trials":726,"activeCount":74},[],{"trials":728,"activeCount":74},[],{"intervention":730,"totalTrials":108,"cells":731},"tyrosine, green tea, caffeine",{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":733,"activeCount":74},[],{"trials":735,"activeCount":74},[736],{"nctId":737,"briefTitle":738,"status":100,"phases":739,"completion":740,"start":741,"enrollment":28,"conditions":742,"interventions":743},"NCT00302289","B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients",[63],"2000-12","2000-01",[15],[730],{"trials":745,"activeCount":74},[],{"trials":747,"activeCount":74},[],{"trials":749,"activeCount":74},[],{"trials":751,"activeCount":74},[],{"intervention":753,"totalTrials":108,"cells":754},"Papaverine or placebo",{"EARLY_PHASE1":755,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":756,"activeCount":74},[757],{"nctId":758,"briefTitle":759,"status":380,"phases":760,"primaryCompletion":761,"completion":762,"start":763,"enrollment":9,"conditions":764,"interventions":767},"NCT01813955","Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia",[62],"2013-05","2013-06","2011-06",[765,766],"Schizophrenia","Cognitive Deficits",[753],{"trials":769,"activeCount":74},[],{"trials":771,"activeCount":74},[],{"trials":773,"activeCount":74},[],{"trials":775,"activeCount":74},[],{"trials":777,"activeCount":74},[],{"intervention":779,"totalTrials":780,"cells":781},"Salbutamol",4,{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":783,"activeCount":74},[],{"trials":785,"activeCount":74},[],{"trials":787,"activeCount":74},[],{"trials":789,"activeCount":74},[],{"trials":791,"activeCount":74},[],{"trials":793,"activeCount":74},[794,803,813,822],{"nctId":795,"briefTitle":796,"status":100,"phases":797,"primaryCompletion":798,"completion":799,"start":486,"enrollment":19,"conditions":800,"interventions":802},"NCT02551276","Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy",[67],"2014-11","2015-11",[801],"Muscle Hypertrophy in Healthy Young Men",[779],{"nctId":804,"briefTitle":805,"status":316,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":811},"NCT03902106","Physiological Response to Salbutamol and Exercise",[67],"2021-06-30","2019-03-28",40,[18],[812],"salbutamol",{"nctId":814,"briefTitle":815,"status":100,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":33,"conditions":819,"interventions":820},"NCT04558190","Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle",[67],"2021-11-01","2020-09-02",[30],[821,779],"Intralipid, 20% Intravenous Emulsion",{"nctId":823,"briefTitle":824,"status":316,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":487,"conditions":828,"interventions":829},"NCT04615611","Physiologic Performance Response to Salbutamol",[67],"2021-11-07","2020-11-07",[18],[812],{"intervention":831,"totalTrials":70,"cells":832},"Terbutaline",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":834,"activeCount":74},[],{"trials":836,"activeCount":74},[],{"trials":838,"activeCount":74},[],{"trials":840,"activeCount":74},[],{"trials":842,"activeCount":74},[],{"trials":844,"activeCount":74},[845,854],{"nctId":846,"briefTitle":847,"status":100,"phases":848,"primaryCompletion":849,"completion":849,"start":850,"enrollment":33,"conditions":851,"interventions":853},"NCT02712658","Role of K+ and Ca2+ in Development of Muscle Fatigue",[67],"2016-03","2015-09",[852],"Skeletal Muscle Fatigue in Humans",[831],{"nctId":855,"briefTitle":856,"status":316,"phases":857,"primaryCompletion":858,"completion":859,"start":860,"enrollment":861,"conditions":862,"interventions":863},"NCT02557581","cAMP Signaling and Muscle Adaptations",[67],"2017-06-30","2017-10","2015-07",72,[801],[831,864],"Clenbuterol",{"intervention":866,"totalTrials":70,"cells":867},"GLP-1",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":869,"activeCount":74},[],{"trials":871,"activeCount":74},[],{"trials":873,"activeCount":74},[],{"trials":875,"activeCount":74},[],{"trials":877,"activeCount":74},[],{"trials":879,"activeCount":74},[880,892],{"nctId":881,"briefTitle":882,"status":100,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":593,"conditions":887,"interventions":889},"NCT06194955","The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function",[67],"2025-12-10","2026-04-01","2023-01-04",[888],"Incretin Effect",[890,866,891],"GIP","GLP-2",{"nctId":893,"briefTitle":894,"status":100,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":90,"conditions":898,"interventions":899},"NCT00940134","Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.",[67],"2012-01","2011-03",[15],[900,866,901],"PYY 3-36","saline",{"intervention":903,"totalTrials":70,"cells":904},"Escitalopram",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":923},{"trials":906,"activeCount":74},[],{"trials":908,"activeCount":74},[],{"trials":910,"activeCount":74},[],{"trials":912,"activeCount":74},[],{"trials":914,"activeCount":74},[915],{"nctId":916,"briefTitle":917,"status":100,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":512,"conditions":921,"interventions":922},"NCT00386841","Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression",[66],"2009-06","2007-04",[18],[903],{"trials":924,"activeCount":74},[925],{"nctId":926,"briefTitle":927,"status":100,"phases":928,"primaryCompletion":929,"completion":929,"start":930,"enrollment":809,"conditions":931,"interventions":933},"NCT00206934","The Effects of Increased Central Serotonergic Activity on Information Processing",[67],"2006-03","2005-03",[932],"Healthy Volunteers",[903,934],"escitaolpram",{"intervention":936,"totalTrials":70,"cells":937},"aripiprazole",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":958},{"trials":939,"activeCount":74},[],{"trials":941,"activeCount":74},[],{"trials":943,"activeCount":74},[],{"trials":945,"activeCount":74},[],{"trials":947,"activeCount":74},[948],{"nctId":949,"briefTitle":950,"status":100,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":956},"NCT02339844","Pan European Collaboration on Antipsychotic Naïve Schizophrenia II",[66],"2021-01","2014-01",130,[765],[957],"Aripiprazole",{"trials":959,"activeCount":74},[960],{"nctId":961,"briefTitle":962,"status":100,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":969},"NCT01154829","Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)",[67],"2014-05","2016-05","2008-12",136,[765],[970,936],"amisulpride",{"intervention":972,"totalTrials":108,"cells":973},"Pulse flour",{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":975,"activeCount":74},[],{"trials":977,"activeCount":74},[],{"trials":979,"activeCount":74},[],{"trials":981,"activeCount":74},[],{"trials":983,"activeCount":74},[],{"trials":985,"activeCount":74},[986],{"nctId":987,"briefTitle":988,"status":100,"phases":989,"primaryCompletion":807,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":994},"NCT04922125","Food Structure of Pulses and Satiety",[67],"2021-07-31","2021-06-01",26,[719],[972,995],"Pre-processed pulse flour",{"intervention":995,"totalTrials":108,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":999,"activeCount":74},[],{"trials":1001,"activeCount":74},[],{"trials":1003,"activeCount":74},[],{"trials":1005,"activeCount":74},[],{"trials":1007,"activeCount":74},[],{"trials":1009,"activeCount":74},[1010],{"nctId":987,"briefTitle":988,"status":100,"phases":1011,"primaryCompletion":807,"completion":990,"start":991,"enrollment":992,"conditions":1012,"interventions":1013},[67],[719],[972,995],{"intervention":1015,"totalTrials":108,"cells":1016},"Probiotic lactobacilli reuteri",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1018,"activeCount":74},[],{"trials":1020,"activeCount":74},[],{"trials":1022,"activeCount":74},[],{"trials":1024,"activeCount":74},[],{"trials":1026,"activeCount":74},[],{"trials":1028,"activeCount":74},[1029],{"nctId":1030,"briefTitle":1031,"status":100,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":659,"enrollment":1034,"conditions":1035,"interventions":1038},"NCT01743690","The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus",[67],"2015-12",25,[1036,1037],"Oral Lichen Planus","Candida Infection",[1015,1039,1040],"Nystatin","fluocinolone",{"intervention":1039,"totalTrials":108,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1044,"activeCount":74},[],{"trials":1046,"activeCount":74},[],{"trials":1048,"activeCount":74},[],{"trials":1050,"activeCount":74},[],{"trials":1052,"activeCount":74},[],{"trials":1054,"activeCount":74},[1055],{"nctId":1030,"briefTitle":1031,"status":100,"phases":1056,"primaryCompletion":1033,"completion":1033,"start":659,"enrollment":1034,"conditions":1057,"interventions":1058},[67],[1036,1037],[1015,1039,1040],{"intervention":1040,"totalTrials":108,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1062,"activeCount":74},[],{"trials":1064,"activeCount":74},[],{"trials":1066,"activeCount":74},[],{"trials":1068,"activeCount":74},[],{"trials":1070,"activeCount":74},[],{"trials":1072,"activeCount":74},[1073],{"nctId":1030,"briefTitle":1031,"status":100,"phases":1074,"primaryCompletion":1033,"completion":1033,"start":659,"enrollment":1034,"conditions":1075,"interventions":1076},[67],[1036,1037],[1015,1039,1040],{"intervention":890,"totalTrials":108,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1080,"activeCount":74},[],{"trials":1082,"activeCount":74},[],{"trials":1084,"activeCount":74},[],{"trials":1086,"activeCount":74},[],{"trials":1088,"activeCount":74},[],{"trials":1090,"activeCount":74},[1091],{"nctId":881,"briefTitle":882,"status":100,"phases":1092,"primaryCompletion":884,"completion":885,"start":886,"enrollment":593,"conditions":1093,"interventions":1094},[67],[888],[890,866,891],{"intervention":891,"totalTrials":108,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1098,"activeCount":74},[],{"trials":1100,"activeCount":74},[],{"trials":1102,"activeCount":74},[],{"trials":1104,"activeCount":74},[],{"trials":1106,"activeCount":74},[],{"trials":1108,"activeCount":74},[1109],{"nctId":881,"briefTitle":882,"status":100,"phases":1110,"primaryCompletion":884,"completion":885,"start":886,"enrollment":593,"conditions":1111,"interventions":1112},[67],[888],[890,866,891],{"intervention":1114,"totalTrials":108,"cells":1115},"Colchicine",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1117,"activeCount":74},[],{"trials":1119,"activeCount":74},[],{"trials":1121,"activeCount":74},[],{"trials":1123,"activeCount":74},[],{"trials":1125,"activeCount":74},[],{"trials":1127,"activeCount":74},[1128],{"nctId":1129,"briefTitle":1130,"status":100,"phases":1131,"primaryCompletion":1132,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1138},"NCT04303689","Repurposing Colchicine to Improve Vascular Function in Hypertension",[67],"2022-12-01","2023-02-28","2020-08-01",31,[1137],"Essential Hypertension",[1114],{"intervention":1140,"totalTrials":108,"cells":1141},"Diet + laxative",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1143,"activeCount":74},[],{"trials":1145,"activeCount":74},[],{"trials":1147,"activeCount":74},[],{"trials":1149,"activeCount":74},[],{"trials":1151,"activeCount":74},[],{"trials":1153,"activeCount":74},[1154],{"nctId":1155,"briefTitle":1156,"status":100,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":521,"conditions":1160,"interventions":1163},"NCT06022302","Effects of Changing Intestinal Transit Time on Gut Microbial Composition and Metabolism",[67],"2024-11-29","2023-10-03",[1161,1162],"Diet, Healthy","Metabolic Disease",[1140],{"intervention":1165,"totalTrials":108,"cells":1166},"Tablet Sitagliptin 100mg",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1168,"activeCount":74},[],{"trials":1170,"activeCount":74},[],{"trials":1172,"activeCount":74},[],{"trials":1174,"activeCount":74},[],{"trials":1176,"activeCount":74},[],{"trials":1178,"activeCount":74},[1179],{"nctId":1180,"briefTitle":1181,"status":316,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":320,"enrollment":90,"conditions":1184,"interventions":1186},"NCT02940184","GLP-1 Signaling in Truncally Vagotomized Subjects",[67],"2018-10",[1185],"Physiology",[1165],{"intervention":934,"totalTrials":108,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1190,"activeCount":74},[],{"trials":1192,"activeCount":74},[],{"trials":1194,"activeCount":74},[],{"trials":1196,"activeCount":74},[],{"trials":1198,"activeCount":74},[],{"trials":1200,"activeCount":74},[1201],{"nctId":926,"briefTitle":927,"status":100,"phases":1202,"primaryCompletion":929,"completion":929,"start":930,"enrollment":809,"conditions":1203,"interventions":1204},[67],[932],[903,934],{"intervention":1206,"totalTrials":108,"cells":1207},"Formoterol",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1218},{"trials":1209,"activeCount":74},[],{"trials":1211,"activeCount":74},[],{"trials":1213,"activeCount":74},[],{"trials":1215,"activeCount":74},[],{"trials":1217,"activeCount":74},[],{"trials":1219,"activeCount":74},[1220],{"nctId":1221,"briefTitle":1222,"status":316,"phases":1223,"primaryCompletion":1224,"completion":1224,"start":1225,"enrollment":321,"conditions":1226,"interventions":1227},"NCT04616261","Beta2-adrenergic System and Training",[67],"2022-11-10","2020-11-10",[18],[1206],{"intervention":1229,"totalTrials":108,"cells":1230},"Analysis of selected single nucleotide polymorphisms",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1232,"activeCount":74},[],{"trials":1234,"activeCount":74},[],{"trials":1236,"activeCount":74},[],{"trials":1238,"activeCount":74},[],{"trials":1240,"activeCount":74},[],{"trials":1242,"activeCount":74},[1243],{"nctId":1244,"briefTitle":1245,"status":100,"phases":1246,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1265},"NCT03225950","Interaction Between Immune Cells and Bacteria Associated With Periodontitis",[],"2018-10-12","2020-03-23","2017-02-01",90,[1252,1253,1254,1255,1256,1257,1258,1259,1260,1261,1262,1263,1264],"Periodontal Diseases","Periodontitis","Aggressive Periodontitis","Immunologic Disease","Microbial Disease","Periodontal Pocket","Inflammation","Inflammation Gum","Dysbiosis","Rheumatoid Arthritis","Generalized Aggressive Periodontitis","Generalized Chronic Periodontitis","Chronic Periodontitis",[1229],{"intervention":864,"totalTrials":108,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1269,"activeCount":74},[],{"trials":1271,"activeCount":74},[],{"trials":1273,"activeCount":74},[],{"trials":1275,"activeCount":74},[],{"trials":1277,"activeCount":74},[],{"trials":1279,"activeCount":74},[1280],{"nctId":855,"briefTitle":856,"status":316,"phases":1281,"primaryCompletion":858,"completion":859,"start":860,"enrollment":861,"conditions":1282,"interventions":1283},[67],[801],[831,864],{"intervention":1285,"totalTrials":108,"cells":1286},"peripheral Peptide YY administration",{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1288,"activeCount":74},[],{"trials":1290,"activeCount":74},[],{"trials":1292,"activeCount":74},[],{"trials":1294,"activeCount":74},[],{"trials":1296,"activeCount":74},[],{"trials":1298,"activeCount":74},[1299],{"nctId":1300,"briefTitle":1301,"status":100,"phases":1302,"completion":1303,"start":930,"enrollment":90,"conditions":1304,"interventions":1305},"NCT00259233","The Role of Peptide YY (PYY)in Inhibiting Food Intake.",[67],"2005-05",[15],[1285],{"intervention":970,"totalTrials":108,"cells":1307},{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1309,"activeCount":74},[],{"trials":1311,"activeCount":74},[],{"trials":1313,"activeCount":74},[],{"trials":1315,"activeCount":74},[],{"trials":1317,"activeCount":74},[],{"trials":1319,"activeCount":74},[1320],{"nctId":961,"briefTitle":962,"status":100,"phases":1321,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":1322,"interventions":1323},[67],[765],[970,936],{"intervention":1325,"totalTrials":108,"cells":1326},"Semaglutide",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1328,"activeCount":74},[],{"trials":1330,"activeCount":74},[],{"trials":1332,"activeCount":74},[],{"trials":1334,"activeCount":74},[],{"trials":1336,"activeCount":74},[],{"trials":1338,"activeCount":74},[1339],{"nctId":1340,"briefTitle":1341,"status":316,"phases":1342,"primaryCompletion":89,"completion":1343,"start":1344,"enrollment":321,"conditions":1345,"interventions":1346},"NCT04383197","Exercise and GLP-1 RA on Insulin Secretion",[67],"2022-08","2019-12-10",[32],[1325],{"intervention":1348,"totalTrials":108,"cells":1349},"NSAID",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1351,"activeCount":74},[],{"trials":1353,"activeCount":74},[],{"trials":1355,"activeCount":74},[],{"trials":1357,"activeCount":74},[],{"trials":1359,"activeCount":74},[],{"trials":1361,"activeCount":74},[1362],{"nctId":1363,"briefTitle":1364,"status":1365,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":74,"conditions":1369,"interventions":1373},"NCT03974984","Anesthesia and Immunological and Oxidative Stress in Relation to Abdominal Cancer Surgery","WITHDRAWN",[],"2020-12-31","2020-06-04",[1370,1371,1372],"Anesthesia","Colon Cancer","Surgery",[1348],{"intervention":1375,"totalTrials":108,"cells":1376},"Nicorandil",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1385,"NA":1387},{"trials":1378,"activeCount":74},[],{"trials":1380,"activeCount":74},[],{"trials":1382,"activeCount":74},[],{"trials":1384,"activeCount":74},[],{"trials":1386,"activeCount":74},[],{"trials":1388,"activeCount":74},[1389],{"nctId":1390,"briefTitle":1391,"status":100,"phases":1392,"primaryCompletion":1393,"completion":1393,"start":1394,"enrollment":660,"conditions":1395,"interventions":1396},"NCT03775902","Regulation of KATP Channels and Na+\u002FK+ ATPase in Relation to Fatigue Development",[67],"2020-01-01","2018-12-19",[30],[1375],{"intervention":1398,"totalTrials":108,"cells":1399},"Combined nutrition and education",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1401,"activeCount":74},[],{"trials":1403,"activeCount":74},[],{"trials":1405,"activeCount":74},[],{"trials":1407,"activeCount":74},[],{"trials":1409,"activeCount":74},[],{"trials":1411,"activeCount":74},[1412],{"nctId":1413,"briefTitle":1414,"status":100,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1421},"NCT06002620","Healthynsect Child Growth and Health Intervention Study",[67],"2024-01-16","2023-03-09",284,[1420],"Nutrition Status",[1398],{"intervention":821,"totalTrials":108,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1425,"activeCount":74},[],{"trials":1427,"activeCount":74},[],{"trials":1429,"activeCount":74},[],{"trials":1431,"activeCount":74},[],{"trials":1433,"activeCount":74},[],{"trials":1435,"activeCount":74},[1436],{"nctId":814,"briefTitle":815,"status":100,"phases":1437,"primaryCompletion":817,"completion":817,"start":818,"enrollment":33,"conditions":1438,"interventions":1439},[67],[30],[821,779],{"intervention":1441,"totalTrials":108,"cells":1442},"Enalapril",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1444,"activeCount":74},[],{"trials":1446,"activeCount":74},[],{"trials":1448,"activeCount":74},[],{"trials":1450,"activeCount":74},[],{"trials":1452,"activeCount":74},[],{"trials":1454,"activeCount":74},[1455],{"nctId":1456,"briefTitle":1457,"status":100,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1464},"NCT03949075","Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity",[67],"2019-12-30","2019-05-15",52,[106,1463],"Angiotensin-Converting Enzyme Inhibitors",[1441],{"intervention":1466,"totalTrials":108,"cells":1467},"Tramadol",{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1469,"activeCount":74},[],{"trials":1471,"activeCount":74},[],{"trials":1473,"activeCount":74},[],{"trials":1475,"activeCount":74},[],{"trials":1477,"activeCount":74},[],{"trials":1479,"activeCount":74},[1480],{"nctId":1481,"briefTitle":1482,"status":100,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":660,"conditions":1486,"interventions":1488},"NCT03934411","Effect of Increased Pain Tolerance on Exercise Performance",[67],"2019-03-07","2018-03-01",[1487,106],"Opioid Use",[1466],{"intervention":1490,"totalTrials":108,"cells":1491},"Peptide YY",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":74},[],{"trials":1495,"activeCount":74},[],{"trials":1497,"activeCount":74},[],{"trials":1499,"activeCount":74},[],{"trials":1501,"activeCount":74},[],{"trials":1503,"activeCount":74},[1504],{"nctId":1505,"briefTitle":1506,"status":100,"phases":1507,"completion":683,"start":1508,"enrollment":90,"conditions":1509,"interventions":1510},"NCT00259246","The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.",[67],"2004-06",[15],[1490],{"intervention":900,"totalTrials":108,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1514,"activeCount":74},[],{"trials":1516,"activeCount":74},[],{"trials":1518,"activeCount":74},[],{"trials":1520,"activeCount":74},[],{"trials":1522,"activeCount":74},[],{"trials":1524,"activeCount":74},[1525],{"nctId":893,"briefTitle":894,"status":100,"phases":1526,"primaryCompletion":896,"completion":896,"start":897,"enrollment":90,"conditions":1527,"interventions":1528},[67],[15],[900,866,901],{"intervention":901,"totalTrials":108,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1532,"activeCount":74},[],{"trials":1534,"activeCount":74},[],{"trials":1536,"activeCount":74},[],{"trials":1538,"activeCount":74},[],{"trials":1540,"activeCount":74},[],{"trials":1542,"activeCount":74},[1543],{"nctId":893,"briefTitle":894,"status":100,"phases":1544,"primaryCompletion":896,"completion":896,"start":897,"enrollment":90,"conditions":1545,"interventions":1546},[67],[15],[900,866,901],{"intervention":1548,"totalTrials":108,"cells":1549},"L. retueri",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1551,"activeCount":74},[],{"trials":1553,"activeCount":74},[],{"trials":1555,"activeCount":74},[],{"trials":1557,"activeCount":74},[],{"trials":1559,"activeCount":74},[],{"trials":1561,"activeCount":74},[1562],{"nctId":1563,"briefTitle":1564,"status":100,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1572},"NCT01738958","Effect of Lozenges Containing Probiotic Lactobacilli on Enamel Demineralization Assed by QLF",[67],"2013-07","2014-03","2012-09",66,[1571],"Caries Dentalis",[1548],{"intervention":1574,"totalTrials":108,"cells":1575},"Whole exome sequencing",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1577,"activeCount":74},[],{"trials":1579,"activeCount":74},[],{"trials":1581,"activeCount":74},[],{"trials":1583,"activeCount":74},[],{"trials":1585,"activeCount":74},[],{"trials":1587,"activeCount":74},[1588],{"nctId":1589,"briefTitle":1590,"status":316,"phases":1591,"primaryCompletion":1592,"completion":1593,"start":1594,"enrollment":33,"conditions":1595,"interventions":1597},"NCT03979833","Drivers of Hypoxia-induced Angiogenesis in Tumor Development",[],"2019-08-31","2020-05-31","2019-06-14",[1596],"Von Hippel-Lindau Disease",[1574],{"intervention":1599,"totalTrials":108,"cells":1600},"Clenbuterol Oral Product",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1602,"activeCount":74},[],{"trials":1604,"activeCount":74},[],{"trials":1606,"activeCount":74},[],{"trials":1608,"activeCount":74},[],{"trials":1610,"activeCount":74},[],{"trials":1612,"activeCount":74},[1613],{"nctId":1614,"briefTitle":1615,"status":100,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":660,"conditions":1619,"interventions":1620},"NCT03860870","Response to Clenbuterol in Humans",[67],"2022-12-21","2019-03-11",[18],[1599],{"intervention":1622,"totalTrials":108,"cells":1623},"Recombinant human erythropoietin",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1625,"activeCount":74},[],{"trials":1627,"activeCount":74},[],{"trials":1629,"activeCount":74},[],{"trials":1631,"activeCount":74},[],{"trials":1633,"activeCount":74},[],{"trials":1635,"activeCount":74},[1636],{"nctId":1637,"briefTitle":1638,"status":100,"phases":1639,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":28,"conditions":1642,"interventions":1645},"NCT05833477","Tracing Changed Production of Red Blood Cells",[67],"2022-12-16","2022-10-28",[1643,1644],"Erythrocytosis","Erythropoiesis Abnormal",[1622],{"intervention":1647,"totalTrials":108,"cells":1648},"EPO",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1650,"activeCount":74},[],{"trials":1652,"activeCount":74},[],{"trials":1654,"activeCount":74},[],{"trials":1656,"activeCount":74},[],{"trials":1658,"activeCount":74},[],{"trials":1660,"activeCount":74},[1661],{"nctId":1662,"briefTitle":1663,"status":316,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1671},"NCT04965961","The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females",[67],"2021-05-17","2024-01","2019-08-28",48,[1670],"Sports Drug Abuse",[1647]]